Overview

QUILT-3.088: NANT Pancreatic Cancer Vaccine

Status:
Withdrawn

Trial end date:
2019-12-30

Target enrollment:

Participant gender:

Summary

QUILT-3.088 NANT Pancreatic Cancer Vaccine: Phase II Randomized Trial of the NANT Pancreatic Cancer Vaccine vs. Standard-of-Care as First- Line Treatment for Patients with Metastatic Pancreatic Cancer.

Phase:

Phase 2

Details

Lead Sponsor:

ImmunityBio, Inc.
NantKwest, Inc.

Treatments:

Albumin-Bound Paclitaxel
Avelumab
Bevacizumab
Capecitabine
Cyclophosphamide
Fluorouracil
Gemcitabine
Leucovorin
Oxaliplatin
Paclitaxel
Vaccines